Generated August 9, 2026.
Overview
ARKG and HLTH are both actively managed healthcare equity ETFs with identical expense ratios, but they target fundamentally different innovation themes. ARKG focuses on genomics, gene editing, and molecular diagnostics — a 10-year-old strategy with $1.65B in assets. HLTH pursues AI-driven applications across drug discovery, diagnostics, medical imaging, and healthcare IT — a brand-new fund launched in mid-2026 with $2.30M in assets. The two funds' underlying companies may overlap, but their selection criteria and thematic focus differ sharply.
How they differ
ARKG's core bet is genomic science and CRISPR-based therapies; HLTH's is artificial intelligence infrastructure applied to healthcare problems. That's the sharpest distinction. Second, ARKG trades with a beta of 2.38 — more than twice as volatile as the broad market — while HLTH's beta of 1.086 suggests it moves closer to market speed. ARKG has accumulated $1.65B in assets over a decade; HLTH launched in July 2026 and holds only $2.30M, a material difference in liquidity and fund maturity. Both charge 0.75% annually, so cost is a wash.
Who each is best for
ARKG: Fits investors with high risk tolerance who believe genomic breakthroughs and gene-editing technologies will drive long-term returns, and who are comfortable with concentrated exposure to early-stage therapeutic innovation over a multi-year horizon.
HLTH: Designed for investors interested in AI's role in healthcare efficiency and drug development, with moderate risk tolerance and a time horizon long enough to wait for an early-stage fund to establish track record and scale.
Key risks to know
- Genomic and gene-therapy concentration (ARKG). The fund's focused mandate means it holds a narrow slice of healthcare innovation. If CRISPR or gene-editing approaches face regulatory setbacks or clinical trial failures, the portfolio has limited diversification into other therapeutic modalities.
- Extreme volatility in ARKG. A beta of 2.38 means a 10% market decline could translate to a ~24% NAV drop in ARKG, compounding losses during downturns. Investors should expect drawdowns twice as severe as the broader market.
- Liquidity and NAV premium/discount risk in HLTH. At $2.30M in assets, HLTH is a micro-cap fund with minimal trading volume. Wide bid-ask spreads are likely, and the fund may trade at a significant discount to NAV if redemptions accelerate or if the AI-in-healthcare narrative cools.
- Early performance history for HLTH. Launched mid-2026, HLTH has no track record beyond a few months. The fund manager's ability to identify AI winners in healthcare and time entry points remains unproven.
- Thematic crowding. Both funds operate in popular innovation narratives. If investor appetite for genomics or healthcare AI retreats, both could face valuation compression independent of their underlying companies' fundamentals.
Bottom line
If you want exposure to genomic science and gene-editing with a proven decade-long track record, ARKG offers scale and liquidity — at the cost of high volatility. If you're drawn to AI's emerging role in healthcare but can tolerate a nascent fund with minimal assets and untested management, HLTH presents a potential entry point, though its extreme thinness carries material trading and redemption risks. Past performance does not guarantee future results; both funds' innovation-driven strategies carry significant execution risk.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
